Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4A | O75164 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7420624 | 1.00 | KDM4A (0.54) | KDM4AMEN1KMT2APOLBCYP2C19 | |
| SCHEMBL10148012 | 0.86 | MEN1 (0.50) | KDM4AMEN1KMT2APOLBCYP2C19 | |
| SCHEMBL22290853 | 0.83 | ALDH1A1 (0.50) | KDM4AMEN1KMT2APOLBCYP2C19 | |
| SCHEMBL8125440 | 0.83 | KDM4A (0.51) | KDM4AMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL8125444 | 0.83 | KDM4A (0.51) | KDM4AMEN1KMT2APOLBALDH1A1 | |
| SCHEMBL649126 | 0.82 | ACE (0.53) | KDM4A | |
| SCHEMBL648928 | 0.82 | ACE (0.53) | KDM4A | |
| SCHEMBL30829406 | 0.82 | ACE (0.53) | KDM4A | |
| SCHEMBL30829401 | 0.82 | ACE (0.53) | KDM4A | |
| SCHEMBL391142 | 0.82 | ACE (0.53) | KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833382-B2 | By muta-synthesis using a mutated micro-organism to influence the biosynthesis of at least one of the precursors of group B streptogramines; mutant strain employed is preferably derived from the strain S. pristinaespiralis SP92 | AVENTIS PHARMA S.A. (FR) | 2004-12-21 | — | — | US | disclosed |
| WO-1996036596-A1 | 3,4-DISUBSTITUTED-PHENYLSULPHONAMIDES AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-21 | — | — | WO | disclosed |